369 related articles for article (PubMed ID: 30848854)
21. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
22. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
23. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.
Bourreille A; Ignjatovic A; Aabakken L; Loftus EV; Eliakim R; Pennazio M; Bouhnik Y; Seidman E; Keuchel M; Albert JG; Ardizzone S; Bar-Meir S; Bisschops R; Despott EJ; Fortun PF; Heuschkel R; Kammermeier J; Leighton JA; Mantzaris GJ; Moussata D; Lo S; Paulsen V; Panés J; Radford-Smith G; Reinisch W; Rondonotti E; Sanders DS; Swoger JM; Yamamoto H; Travis S; Colombel JF; Van Gossum A;
Endoscopy; 2009 Jul; 41(7):618-37. PubMed ID: 19588292
[TBL] [Abstract][Full Text] [Related]
24. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
25. Medical Management of Inflammatory Bowel Disease.
Rahman S; Patel RK; Boden E; Tsikitis VL
Surg Clin North Am; 2024 Jun; 104(3):657-671. PubMed ID: 38677828
[TBL] [Abstract][Full Text] [Related]
26. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
[TBL] [Abstract][Full Text] [Related]
27. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
Rencz F; Péntek M; Bortlik M; Zagorowicz E; Hlavaty T; Śliwczyński A; Diculescu MM; Kupcinskas L; Gecse KB; Gulácsi L; Lakatos PL
World J Gastroenterol; 2015 Feb; 21(6):1728-37. PubMed ID: 25684937
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory bowel disease: long-term therapeutic challenges.
Ashton JJ; Green Z; Kolimarala V; Beattie RM
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1049-1063. PubMed ID: 31657969
[No Abstract] [Full Text] [Related]
29. Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.
Sartini A; Scaioli E; Liverani E; Bellanova M; Ricciardiello L; Bazzoli F; Belluzzi A
Dig Dis Sci; 2019 Mar; 64(3):863-874. PubMed ID: 30334112
[TBL] [Abstract][Full Text] [Related]
30. SURGICAL MANAGEMENT OF ADULT CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS: A CONSENSUS FROM THE BRAZILIAN ORGANIZATION OF CROHN'S DISEASE AND COLITIS (GEDIIB).
Zabot GP; Cassol OS; Quaresma AB; Gonçalves Filho FA; Baima JP; Imbrizi M; Rolim AS; Carmo AMD; Alves Junior AJT; Santos CHMD; Sobrado Junior CW; Miranda EF; Albuquerque IC; Souza MM; Kaiser Junior RL; Parra RS; Kotze PG; Saad-Hossne R
Arq Gastroenterol; 2023; 59(suppl 1):1-19. PubMed ID: 36995887
[TBL] [Abstract][Full Text] [Related]
31. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.
Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
J Gastroenterol Hepatol; 2018 Jan; 33(1):30-36. PubMed ID: 29024102
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory Bowel Disease and Risk of Birth Defects in Offspring.
Auger N; Côté-Daigneault J; Bilodeau-Bertrand M; Arbour L
J Crohns Colitis; 2020 Jun; 14(5):588-594. PubMed ID: 31907519
[TBL] [Abstract][Full Text] [Related]
33. Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature.
Yadav A; Foromera J; Falchuk KR; Feuerstein JD
Scand J Gastroenterol; 2018; 53(7):813-817. PubMed ID: 29719998
[TBL] [Abstract][Full Text] [Related]
34. Updates in therapeutic drug monitoring in inflammatory bowel disease.
Lodhia N; Rao S
World J Gastroenterol; 2022 Jun; 28(21):2282-2290. PubMed ID: 35800180
[TBL] [Abstract][Full Text] [Related]
35. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.
Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
Biopharm Drug Dispos; 2019 Jul; 40(7):250-261. PubMed ID: 31256430
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.
Kirsner JB
Dis Mon; 1991 Nov; 37(11):669-746. PubMed ID: 1935537
[TBL] [Abstract][Full Text] [Related]
37. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.
Nguyen GC; Harris ML; Dassopoulos T
Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of inflammatory bowel disease in Asia.
Yang SK; Loftus EV; Sandborn WJ
Inflamm Bowel Dis; 2001 Aug; 7(3):260-70. PubMed ID: 11515854
[TBL] [Abstract][Full Text] [Related]
39. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
40. Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile.
Di Sario A; Bendia E; Schiadà L; Sassaroli P; Benedetti A
Curr Drug Saf; 2016; 11(1):55-61. PubMed ID: 26882354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
